Results 111 to 120 of about 8,661 (182)

In Vitro Screening of Anti-Viral and Virucidal Effects Against SARS-CoV-2 by Phenylamino-Phenoxy-Quinoline Derivatives: An Integrative Computational Approach [PDF]

This study investigated the binding interactions between three groups of 2,4-disubstituted phenylamino-phenoxyquinoline derivatives 1-3(a-d) and four readily available drugs (ritonavir, ensitrelvir, nirmatrelvir, and paxlovid) with severe acute ...
Baicharoen, Apisara, Jittmittraphap, Akanitt, Jityuti, Benchawan, Kuno, Mayuso, Leaungwutiwong, Pornsawan, Makarasen, Arthit, Ngueanngam, Natchaphon, Patnin, Suwicha, Techasakul, Supanna, Vijitphan, Pongsit   +9 more
core   +1 more source

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration .   +17 more
europepmc   +1 more source

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. [PDF]

Front Cell Infect Microbiol
Zhang Y, Yang X, Sun L, Zhang R, Fan W, Lin N, Lin B.   +6 more
europepmc   +1 more source

A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes. [PDF]

Sci Rep
Zhu Z, Chen Q, Wang Z, Chen Q, Li X, Liu Y, Lu H, Feng J, Xie M, Dong X, Chen B, Huang J, Zeng X, Zeng Z, Yuan Y, Xu F, Liao X, Liang B, Chen W.   +18 more
europepmc   +1 more source

Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir. [PDF]

ACS Pharmacol Transl Sci
Tan H, Chi X, Deng X, Wang J.
europepmc   +1 more source

Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. [PDF]

J Am Heart Assoc
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, Lin M, Kwok WC, Lam SC, Chan KE, Un KC, Lam TH, Chu WM, Tam AR, Hung FN, Lip GYH, Tse HF.   +16 more
europepmc   +1 more source

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19 [PDF]

, 2023
Bartoloni, Alessandro, Basile, Gregorio, Campolmi, Irene, Ciurleo, Greta, Coppi, Marco, di Dio, Marta, Graziani, Lucia, Malentacchi, Francesca, Manciulli, Tommaso, Mattei, Marta, Morettini, Alessandro, Parronchi, Paola, Rossolini, Gian Maria, Spinicci, Michele, Tomassetti, Sara   +14 more
core   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study. [PDF]

BMC Infect Dis
Edwards LJ, Scaria A, Cheng AC, Amin J, Robinson EJ, Sumpton C, Liu B.   +6 more
europepmc   +1 more source

Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series [PDF]

, 2023
Bonora, Stefano, Calcagno, Andrea, De Rosa, Francesco Giuseppe, Frascione, Pio Manlio Mirko, Pepe, Andrea, Ponzetta, Laura, Ranzani, Fabio Antonino, Vita, Davide   +7 more
core   +1 more source

Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants. [PDF]

JACS Au
Cai Z, Kohaal N, Georgiou K, Liang X, Chi X, Tan H, Tan B, Li K, Fan G, Lambrinidis G, Kolocouris A, Deng X, Chen Y, Wang J.   +13 more
europepmc   +1 more source